Zynyz access in Lebanon: the MoPH-PDD named-patient pathway
How patients in the Lebanese Republic legally obtain Zynyz (retifanlimab-dlwr) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Patients in Lebanon access Zynyz (retifanlimab-dlwr) for metastatic or recurrent locally advanced Merkel cell carcinoma in adults, and squamous cell carcinoma of the anal canal in combination with chemotherapy through the MoPH-PDD named-patient pathway, a the Pharmacy and Drug Department of the Lebanese Ministry of Public Health-administered mechanism that allows a Lebanese-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in USD.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
Why Lebanese patients need Zynyz through the named-patient pathway
The Lebanese Republic operates a structured pharmaceutical regulatory environment. Zynyz (retifanlimab-dlwr) is regulated through MoPH-PDD (the Pharmacy and Drug Department of the Lebanese Ministry of Public Health) channels, and a Lebanese family asking for Zynyz is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.
Four converging patterns drive these cases. First, indication lag. Zynyz's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. out-of-pocket cash (fresh USD) payment, with limited NSSF (CNSS) coverage for chronic conditions and partial reimbursement under Bankers Assurance, MEDIS, and Allianz SNA private health plans each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Lebanon or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.
In each pattern, the MoPH-PDD named-patient pathway is the mechanism that connects a Lebanese-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Zynyz is a humanized IgG4 monoclonal antibody against programmed cell death receptor 1 (PD-1) that restores T-cell anti-tumor activity, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.
Current regulatory status of Zynyz in Lebanon
Zynyz (retifanlimab-dlwr; Incyte) is a humanised IgG4 anti-programmed-cell-death-receptor-1 (PD-1) monoclonal antibody. FDA approval was first granted in 2023 for adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC); a 2025 supplemental approval added squamous cell carcinoma of the anal canal in combination with chemotherapy. Retifanlimab is administered by 30-minute IV infusion every 4 weeks for MCC monotherapy.
As of 2026-05-31, no public MOPH record of a Lebanon marketing authorisation for retifanlimab has been observed on the MOPH registered drugs list. Several PD-1 inhibitors (pembrolizumab, nivolumab, cemiplimab) are regionally registered through their respective manufacturers; retifanlimab is a more recent entrant and the Lebanon registration timeline is not publicly documented.
Access proceeds through the MOPH Directorate of Pharmacy named-patient channel under Lebanese Pharmacy Profession Law No. 367/1994. The file specifies the histopathologic diagnosis (MCC or anal SCC), the immunohistochemistry profile (Merkel cell polyomavirus status where assessed), staging (TNM stage IV or recurrent), prior therapy history, and the cycle plan (480 mg IV q4w for MCC monotherapy; combination cycles per the anal-SCC labelling for that indication). For the rare-disease MCC indication, prior treatment options in Lebanon (where pembrolizumab or cemiplimab is locally available) and the rationale for retifanlimab over the locally-available PD-1 inhibitors are referenced.
Last verified by ARCH-74: 2026-05-31.
Named tertiary centres in Lebanon where Zynyz is dispensed
Retifanlimab is an adult medical oncology product administered in an infusion centre. For MCC (a cutaneous rare-cancer indication) and anal SCC (a GI / colorectal-oncology indication) the Lebanese tertiary centres are:
- American University of Beirut Medical Center (AUBMC), Beirut - Naef K. Basile Cancer Institute; Department of Medical Oncology with cutaneous-oncology and GI-oncology sub-clinics; the principal academic referral centre for rare cutaneous cancers in Lebanon.
- Hotel-Dieu de France de Beyrouth (USJ), Beirut - Department of Medical Oncology.
- Saint George Hospital University Medical Center, Beirut - Department of Medical Oncology.
- LAU Medical Center - Rizk Hospital, Beirut - Department of Medical Oncology with infusion service.
- Bellevue Medical Center, Mansourieh - private oncology service.
For MCC the dermatopathology referral pattern concentrates at AUBMC; the histopathologic confirmation and Merkel cell polyomavirus immunohistochemistry route through AUBMC pathology even where the patient's care is at another centre.
Local pricing reference for Zynyz in Lebanon
US WAC reference for Zynyz (retifanlimab, 500 mg/20 mL single-dose vial) is in the order of USD 20,000 to USD 25,000 per 480 mg q4w dose for MCC monotherapy. Per-cycle annual reference: approximately USD 240,000 to USD 300,000 at 12 doses per year. Source: Zynyz FDA Prescribing Information.
Where pembrolizumab or cemiplimab is locally available in Lebanon at a regional list price, the patient quotation customarily compares the two routes; for a patient with documented intolerance or progression on a locally-available PD-1 inhibitor, the cross-border Zynyz route is the substantive option.
Price snapshot date: 2026-05-31. Infusion-service overhead, baseline thyroid and hepatic monitoring, and immune-related-adverse-event surveillance are billed separately by the dispensing hospital.
Country-specific access barriers for Zynyz in Lebanon
The principal access pattern for retifanlimab in Lebanon is the prior-PD-1-inhibitor failure or intolerance pathway. Lebanese oncologists at AUBMC and Hotel-Dieu have established protocols for pembrolizumab and cemiplimab in MCC where locally available; retifanlimab as named-patient import is requested where the patient cannot tolerate or has progressed on those agents, or where supply continuity is the driver.
Funding posture: post-2019 fiscal crisis has constrained the MOPH Pharmaceutical Aid Programme; coverage of PD-1 inhibitors for rare cancers is policy-specific. Insurers (MEDGulf, Bankers Insurance, AROPE, Allianz SNA, AXA Middle East) cover PD-1 inhibitors for established indications with case-by-case pre-authorisation; novel-agent-in-rare-indication coverage typically requires explicit demonstrated failure of the locally-available alternative.
The dominant funding pattern for cross-border retifanlimab is patient self-pay in fresh USD supplemented by Incyte regional patient-access programmes where Lebanon is included. Charitable channels at AUBMC (Naef K. Basile Cancer Institute fund) support some MCC and rare-cancer cases. For Syrian and Palestinian refugee oncology patients UNHCR / UNRWA pathways operate; rare-cancer PD-1 therapy is not customarily UNHCR-supplied.
Cold-chain (2 to 8 degree Celsius) is required for the prefilled vial; Beirut Rafic Hariri airport handles refrigerated pharmaceutical clearance. The immune-related-adverse-event monitoring axis (thyroid, hepatic, dermatologic, gastrointestinal, pulmonary, endocrine) is documented in the dispensing-pharmacy clinical pathway.
Recent local regulatory news touching Zynyz or its drug class in Lebanon
No MOPH bulletin specifically naming retifanlimab or the PD-1-inhibitor class has been observed in the last twelve months on the MOPH news and circulars page as of 2026-05-31. Adjacent context:
- FDA labelling expansion of Zynyz from Merkel cell carcinoma into squamous cell carcinoma of the anal canal in 2025 is the most recent class-relevant US regulatory event; regional regulator engagement typically lags US updates. Source: FDA Drugs@FDA database.
- Class-level PD-1-inhibitor pharmacovigilance updates (immune-related adverse events) continue to be tracked. ARCH-74 confirms quarterly that no MOPH-specific restriction has been gazetted. Source: MOPH.
What your physician needs to provide
For a Lebanese-licensed specialist prescribing Zynyz through the MoPH-PDD pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for metastatic or recurrent locally advanced Merkel cell carcinoma in adults, and squamous cell carcinoma of the anal canal in combination with chemotherapy, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Zynyz is the appropriate next step given a humanized IgG4 monoclonal antibody against programmed cell death receptor 1 (PD-1) that restores T-cell anti-tumor activity.
The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Zynyz (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.
The treating physician's Lebanese license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.
Common questions about Zynyz in Lebanon
Will out-of-pocket cash (fresh USD) payment, with limited NSSF (CNSS) coverage for chronic conditions and partial reimbursement under Bankers Assurance, MEDIS, and Allianz SNA private health plans cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Zynyz is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.
Is the FDA-approved indication recognised by MoPH-PDD? The MoPH-PDD named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; MoPH-PDD review focuses on the clinical justification rather than re-litigating the FDA decision.
My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Lebanese-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Lebanese Order of Physicians (Beirut or Tripoli branch) and the MoPH Pharmacy and Drug Department verifies the active license; the MoPH-PDD application records both the prescribing physician and the dispensing facility.
Can I receive Zynyz at home? The dispensing facility must be Lebanese-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.
What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.
Where Reserve Meds fits in Zynyz cases
Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace MoPH-PDD, and we do not replace your dispensing pharmacy. For Zynyz specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Lebanon, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Zynyz case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the MoPH-PDD application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Lebanese tertiary specialty care concentrates at AUBMC, Hotel-Dieu de France, LAU Medical Center-Rizk Hospital, Clemenceau Medical Center, and Mount Lebanon Hospital in Beirut and Hazmieh; following the post-2019 currency crisis, specialty-medicine pricing is quoted predominantly in fresh US dollars, and the MoPH Pharmacy and Drug Department named-patient import authorisation is the standard mechanism for unregistered specialty medicines.
Next step
If your Lebanese physician has prescribed Zynyz and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.